11. Uso de empagliflozina en pacientes  con enfermedad renal crónica

Ignacio Fernández Vidaurreta

Ignacio Fernández Vidaurreta Medicina Familiar y Comunitaria. Hospital de Torrejón

Palabras clave: Empagliflozina, Enfermedad renal, Diabetes, Medicina General, Nefrología, Urología, Urgencias

Abstract

Se diseñó el estudio EMPA-KIDNEY para evaluar los efectos del tratamiento con empagliflozina en pacientes con enfermedad renal crónica. Demostró que su uso conllevó un menor riesgo de progresión de la enfermedad o de muerte por causas cardiovasculares, en comparación con el tratamiento con placebo.

The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in patients with chronic kidney disease. This empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.

Recibido: 06 Abril 2023
Revisión: 11 Abril 2023
Aceptado: 05 Mayo 2023

Citas

Vol 380 N9854; págs. 1662-1673. 2012. Fox CS, Matsushita K, Woodward M, et al. Associations

of kidney disease measures with mortality and end-stage renal disease in individuals with and

without diabetes: a meta-analysis. The Lancet.

Doi: https://doi.org/10.1016/s0140-6736(12)61350-6

Vol 389 N10075; págs. 1238-1252. 2017. Webster AC, Nagler EV, Morton RL, Masson P. Chronic

kidney disease. The Lancet 2017.

Doi: https://doi.org/10.1016/s0140-6736(16)32064-5

Vol 345 N12; págs 861-869. 2001. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of

losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa011161

Vol 345 N12; págs 851-860.2001. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective

effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type

diabetes. The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa011303

Vol 329 N20; págs 1456-1462. 1993. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of

angiotensin-converting-enzyme inhibition on diabetic nephropathy. The New England Journal of

Medicine.

Doi: https://doi.org/10.1056/nejm199311113292004

Vol 380 N24; págs 2295-2306. 2019. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and

renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa1811744

Vol 383 N15; págs 1436-1446. 2020. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.

Dapagliflozin in patients with chronic kidney disease. The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa2024816

Vol 383 N23; págs 2219-2229. 2020. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone

on chronic kidney disease outcomes in type 2 diabetes. The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa2025845